title: Why osteonecrosis of the jaw after bisphosphonates treatment is more frequent in multiple myeloma than in solid tumors.
authors.forename: Tuncay
authors.initials: T
authors.lastname: Delibasi
authors.forename: Kadri
authors.initials: K
authors.lastname: Altundag
authors.forename: Yesim
authors.initials: Y
authors.lastname: Kanlioglu
mesh_terms: D050071:Bone Density Conservation Agents / Q000009:adverse effects* / Q000493:pharmacokinetics; D001859:Bone Neoplasms / Q000150:complications* / Q000188:drug therapy / Q000556:secondary; D001943:Breast Neoplasms / Q000473:pathology; D004164:Diphosphonates / Q000009:adverse effects* / Q000493:pharmacokinetics; D005260:Female; D006801:Humans; D007568:Jaw / Q000378:metabolism; D007571:Jaw Diseases / Q000139:chemically induced* / Q000150:complications / Q000378:metabolism; D009101:Multiple Myeloma / Q000150:complications* / Q000188:drug therapy; D010010:Osteoclasts / Q000378:metabolism; D010020:Osteonecrosis / Q000139:chemically induced* / Q000150:complications / Q000378:metabolism
chemical_list: D050071:Bone Density Conservation Agents; D004164:Diphosphonates